FAT1 and neoplasm: Although the highly mutated FAT1 molecule itself has not been identified as a therapeutic target in HNSCC, due to its nature as a tumor suppressor, these surface receptors and signaling molecules associated with FAT1 mutation are well-investigated therapeutic targets with available targeted agents and possible links to immune-related pathways.